Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology company dedicated to improving cardiovascular health through advanced diagnostic solutions. By harnessing cutting-edge technology, CDIO provides healthcare professionals with essential tools for accurate assessment and effective management of cardiovascular diseases, ultimately enhancing patient outcomes. With a strong focus on personalized medicine, the company is strategically poised for substantial growth, representing a compelling investment opportunity for institutional investors aiming to leverage advancements in the evolving healthcare landscape.
| Revenue (TTM) | 16,560 |
| Gross Profit (TTM) | 16,560 |
| EBITDA | $-6.27M |
| Operating Margin | -66598.00% |
| Return on Equity | -65.60% |
| Return on Assets | -38.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $3.01 |
| Price-to-Book | 0.56 |
| Price-to-Sales (TTM) | 278.71 |
| EV/Revenue | 23.01 |
| EV/EBITDA | -22.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 185.10% |
| Shares Outstanding | $2.96M |
| Float | $2.83M |
| % Insiders | 8.31% |
| % Institutions | 9.34% |
Volatility is currently contracting
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDIO and any ticker you trade — then tracks every position and per-strategy win rate.
